Health Policy & Regulatory Subcategories
Decision & Deliberative Processes (including multi-criteria decision analysis [MCDA])
-
Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions
-
Generative Artificial Intelligence for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations
-
Primer on Health Equity Research in Health Economics and Outcomes Research
-
Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making
-
Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist
-
Evolving Use of Health Technology Assessment in Medical Device Procurement—Global Systematic Review
-
Quantitative Benefit-Risk Assessment in Medical Product Decision Making
-
A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health
-
Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes?
-
Designing and Implementing Deliberative Processes for Health Technology Assessment: Joint HTAi/ISPOR Task Force Report
-
Being Precise About Precision Medicine: Report of the ISPOR Personalized Precision Medicine Special Interest Group
-
Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
-
Challenges in Research and Health Technology Assessment of Rare Disease Technologies:
-
Multiple Criteria Decision Analysis for Health Care Decision Making - An Introduction: Report 1
-
Multiple Criteria Decision Analysis for Health Care Decision Making - Emerging Good Practices: Report 2
-
Transferability of Economic Evaluations Across Jurisdictions - Good research practices task force report
-
Use of Pharmacoeconomics Information
Health Disparities & Equity
Reimbursement & Access Policy
-
Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes?
-
Challenges of Health Technology Assessment in Pluralistic Healthcare Systems
-
Are We Ready For A New Approach To Comparing Coverage And Reimbursement Policies For Medical Nutrition In Key Markets
-
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions - Report of the ISPOR Stated Preference Research Special Interest Group
-
Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research
-
Using Real-World Data for Coverage and Payment Decisions
Risk-Sharing Approaches
All Health Policy & Regulatory Reports
Please Note: Reports are in reverse chronological order.
-
Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions
-
Primer on Health Equity Research in Health Economics and Outcomes Research
-
Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making
-
Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes?
-
Challenges of Health Technology Assessment in Pluralistic Healthcare Systems
-
Are We Ready For A New Approach To Comparing Coverage And Reimbursement Policies For Medical Nutrition In Key Markets
-
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions - Report of the ISPOR Stated Preference Research Special Interest Group
-
Performance-Based Risk-Sharing Arrangements - Good Practices for Design, Implementation and Evaluation
-
Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research
-
Using Real-World Data for Coverage and Payment Decisions